dc.creator | Mavropoulos A., Zafiriou E., Simopoulou T., Brotis A.G., Liaskos C., Roussaki-Schulze A., Katsiari C.G., Bogdanos D.P., Sakkas L.I. | en |
dc.date.accessioned | 2023-01-31T08:58:12Z | |
dc.date.available | 2023-01-31T08:58:12Z | |
dc.date.issued | 2019 | |
dc.identifier | 10.1093/rheumatology/kez204 | |
dc.identifier.issn | 14620324 | |
dc.identifier.uri | http://hdl.handle.net/11615/76447 | |
dc.description.abstract | Objectives: Psoriatic arthritis (PsA) and psoriasis are immune-mediated inflammatory diseases sharing common immunological mechanisms. Regulatory B cells (Breg cells) producing IL-10 (B10 cells), a critical anti-inflammatory B-cell subset, were found to be decreased in both PsA and psoriasis. Apremilast, a phosphodiesterase-4(PDE4) inhibitor, increases IL-10 and therefore, we examined the effect of apremilast on Breg cells. Methods: Fifty patients, including 20 with PsA and 30 with psoriasis, were included in the study. The effect of apremilast on Breg cells at 3, 6 and 12 months post-treatment, was examined by flow cytometry in ODN2006 (TLR9)-stimulated peripheral blood mononuclear cells and magnetically-isolated cells. Th1 cells, Th17 cells and NKT were also measured. Results: Ex vivo stimulated cell analysis identified that post-apremilast (IL-10+CD19+) B10 cells were increased in all PsA and psoriasis patients and correlated with psoriatic skin and joint clinical improvement. Apremilast decreased IFNγ(+) T and NKT cells and IL-17(+)NKT cells. B10 cells also inversely correlated with Th1 cells, and IFNγ(+)NKT cells. Conclusion: These results suggest that Breg cells are a major target of apremilast in PsA and psoriasis and that apremilast-induced increase of Breg cells is associated with a decrease of Th1 cells, IFNγ-producing NKT cells and IL-17-producing NKT cells. © 2019 The Author(s) 2019. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com. | en |
dc.language.iso | en | en |
dc.source | Rheumatology (United Kingdom) | en |
dc.source.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85075812490&doi=10.1093%2frheumatology%2fkez204&partnerID=40&md5=ef387994556fb3033c18a689918393c5 | |
dc.subject | abatacept | en |
dc.subject | adalimumab | en |
dc.subject | apremilast | en |
dc.subject | certolizumab pegol | en |
dc.subject | corticosteroid | en |
dc.subject | disease modifying antirheumatic drug | en |
dc.subject | etanercept | en |
dc.subject | gamma interferon | en |
dc.subject | infliximab | en |
dc.subject | interleukin 10 | en |
dc.subject | tocilizumab | en |
dc.subject | ustekinumab | en |
dc.subject | apremilast | en |
dc.subject | biological marker | en |
dc.subject | IL10 protein, human | en |
dc.subject | interleukin 10 | en |
dc.subject | nonsteroid antiinflammatory agent | en |
dc.subject | thalidomide | en |
dc.subject | adult | en |
dc.subject | aged | en |
dc.subject | Article | en |
dc.subject | cell stimulation | en |
dc.subject | clinical article | en |
dc.subject | controlled study | en |
dc.subject | cytokine production | en |
dc.subject | drug effect | en |
dc.subject | drug mechanism | en |
dc.subject | drug withdrawal | en |
dc.subject | ex vivo study | en |
dc.subject | female | en |
dc.subject | flow cytometry | en |
dc.subject | human | en |
dc.subject | human cell | en |
dc.subject | immunophenotyping | en |
dc.subject | innate immunity | en |
dc.subject | male | en |
dc.subject | middle aged | en |
dc.subject | natural killer T cell | en |
dc.subject | peripheral blood mononuclear cell | en |
dc.subject | priority journal | en |
dc.subject | psoriasis | en |
dc.subject | psoriatic arthritis | en |
dc.subject | regulatory B lymphocyte | en |
dc.subject | T lymphocyte | en |
dc.subject | Th1 cell | en |
dc.subject | Th17 cell | en |
dc.subject | treatment outcome | en |
dc.subject | unspecified side effect | en |
dc.subject | biosynthesis | en |
dc.subject | clinical trial | en |
dc.subject | immunology | en |
dc.subject | innate immunity | en |
dc.subject | lymphocyte count | en |
dc.subject | metabolism | en |
dc.subject | multicenter study | en |
dc.subject | pathology | en |
dc.subject | psoriasis | en |
dc.subject | psoriatic arthritis | en |
dc.subject | regulatory B lymphocyte | en |
dc.subject | T lymphocyte | en |
dc.subject | Adult | en |
dc.subject | Aged | en |
dc.subject | Anti-Inflammatory Agents, Non-Steroidal | en |
dc.subject | Arthritis, Psoriatic | en |
dc.subject | B-Lymphocytes, Regulatory | en |
dc.subject | Biomarkers | en |
dc.subject | Female | en |
dc.subject | Flow Cytometry | en |
dc.subject | Humans | en |
dc.subject | Immunity, Innate | en |
dc.subject | Interleukin-10 | en |
dc.subject | Lymphocyte Count | en |
dc.subject | Male | en |
dc.subject | Middle Aged | en |
dc.subject | Psoriasis | en |
dc.subject | T-Lymphocytes | en |
dc.subject | Thalidomide | en |
dc.subject | Oxford University Press | en |
dc.title | Apremilast increases IL-10-producing regulatory B cells and decreases proinflammatory T cells and innate cells in psoriatic arthritis and psoriasis | en |
dc.type | journalArticle | en |